Timeline of incretin therapeutics (revision 4)
Old revision·14:38, 21 Aug 2024·ExenatideEzra
This is an old revision of this page, as it stood at 14:38, 21 Aug 2024, saved by ExenatideEzra with the summary sentence case in headings per PP:MOS. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Timeline of incretin therapeutics | |
|---|---|
| Span | 1900s to the present |
| Arrangement | Chronological |
| List infobox · conventions | |
This timeline sets out the development of incretin science and of the drugs derived from it, from the earliest observation that oral glucose provokes a larger insulin response than intravenous glucose, to the multi-receptor agonists in development.[1]
Dates are given for the events most consistently reported in the literature. Where a discovery is attributable to a series of publications rather than one, the timeline names the period rather than a single year.[2]
Physiology
[edit]| Period | Event |
|---|---|
| 1900s–1920s | Observation that oral glucose evokes a larger insulin response than intravenous |
| 1960s | The term incretin revived; the enteroinsular axis proposed |
| 1970s | GIP isolated and characterised |
| 1980s | Glucagon-like peptide-1 identified as a proglucagon product and shown to be insulinotropic |
| 1986 | Reduced Incretin effect documented in type 2 diabetes |
| 1990s | Dipeptidyl peptidase-4 identified as the enzyme inactivating both incretins |
The 1986 finding is the hinge of the field: it established that the incretin axis is defective in type 2 diabetes and therefore a therapeutic target rather than only a physiological curiosity.[2]
References
Categories: